Sign In
Buy EDIT
$2.78
-0.0400 (-1.42%)
At Close: Jun 03, 2026
Will Moderna's Interest Boost Gene Editing Stocks?
10:30am, Monday, 16'th Aug 2021
Our indicative theme of Gene Editing stocks has returned about 11% year-to-date, compared to the S&P 500 which is up by about 19% over the same period. However, the gains have overwhelmingly come from
How Are Genomics ETFs Responding to Q2 Earnings?
10:00am, Saturday, 14'th Aug 2021
Let's take a look at some big genomics earnings releases to see if these will impact ETFs exposed to the space.
Will Moderna Buy Editas Medicine to Jump Into Gene Editing?
05:52am, Thursday, 12'th Aug 2021
Editas could be an attractive acquisition candidate for the big vaccine maker.
Why Editas Medicine Beat the Market on Monday
06:05pm, Monday, 09'th Aug 2021
Another analyst ups his recommendation on the stock.
Monday Afternoon Analyst Upgrades and Downgrades: Caesars, Coinbase, Editas, Wynn and More
12:54pm, Monday, 09'th Aug 2021
With the trading day more than halfway over, the broad markets were fairly mixed. While the Dow Jones industrial average and S&P 500 had pulled back slightly from their all-time highs, they still seem
Gene Editing Stocks: Why EDIT, NTLA, CRSP Stocks Are Climbing Today
03:34pm, Thursday, 05'th Aug 2021
Today, investors in gene editing stocks are seeing a lot of green as earnings were announced along with business updates from key players. The post Gene Editing Stocks: Why EDIT, NTLA, CRSP Stocks Are
Editas (EDIT) Q2 Earnings Beat Estimates, Revenues Fall Y/Y
02:28pm, Thursday, 05'th Aug 2021
Editas (EDIT) reports narrower-than-expected loss in the second quarter of 2021 while revenues miss estimates. Focus remains on the development of CRISPR gene-editing candidate, EDIT-101.
Thursday Afternoon Analyst Upgrades and Downgrades: Bath & Body Works, Editas, GoDaddy, PetMed, Qorvo and More
11:50am, Thursday, 05'th Aug 2021
With the trading day about halfway over, S&P 500, Nasdaq and Dow Jones industrial average were pushing higher for a number of reasons.
Editas Medicine, Inc. (EDIT) CEO Jim Mullen on Q2 2021 Results - Earnings Call Transcript
02:39pm, Wednesday, 04'th Aug 2021
Editas Medicine, Inc. (EDIT) CEO Jim Mullen on Q2 2021 Results - Earnings Call Transcript
Editas Medicine (EDIT) Reports Q2 Loss, Misses Revenue Estimates
09:55am, Wednesday, 04'th Aug 2021
Editas (EDIT) delivered earnings and revenue surprises of 4.71% and -94.33%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Editas Medicine (EDIT) Stock Moves -0.1%: What You Should Know
06:59pm, Friday, 30'th Jul 2021
In the latest trading session, Editas Medicine (EDIT) closed at $41.86, marking a -0.1% move from the previous day.
CAMBRIDGE, Mass. and CORALVILLE, Iowa, July 29, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, and Integrated DNA Technologies, Inc. (IDT), a leading
Editas Medicine Names Bruce E. Eaton, Ph.D.
09:00am, Monday, 26'th Jul 2021
Dr. Eaton joined the Company in 2018 and brings more than 30 years of experience to the role
The Top 2 Stocks to Buy to Play the Emerging Exoskeleton Megatrend
05:30pm, Saturday, 24'th Jul 2021
Many science fiction concepts are turning into disruptive realities and creating enormous investment opportunities. The post The Top 2 Stocks to Buy to Play the Emerging Exoskeleton Megatrend appeared
5 Mid-Cap Healthcare Stocks You'll Want on Your Radar for the 2nd Half of 2021
07:01am, Friday, 23'rd Jul 2021
These biotech stocks could have great long-term potential.
